My Size released FY2024 Q2 earnings on August 12 (EST), actual revenue USD 1.979 M (forecast USD 2 M), actual EPS USD -1.2758

Brief Summary

My Size reported a Q2 2024 revenue of $1.98 million, slightly missing the expected $2 million, with an EPS of -$1.2758 per share.

Impact of The News

Financial Performance Analysis

• Revenue Performance: My Size’s reported revenue of $1.98 million was slightly below the expected $2 million.
• Earnings Per Share (EPS): The company’s EPS was reported at -$1.2758, indicating a loss per share.

Comparison with Industry Peers

• The results indicate a challenging quarter for My Size, with negative earnings per share and a slight revenue miss, contrasting with more favorable earnings and revenue trends seen in other companies like Eli Lilly, which experienced a significant 36% revenue growth in the same period driven by successful drug sales .

Business Status and Future Outlook

• Current Business Challenges: The negative EPS suggests that My Size may be experiencing operational or market challenges that are affecting profitability.
• Potential Implications: This could potentially impact investor confidence and may lead to increased scrutiny in subsequent earnings reports.
• Future Outlook: To improve financial metrics, My Size might need to focus on cost management or seek strategic partnerships to enhance revenue streams. The company may also explore innovative product offerings or market expansion to reverse the negative earnings trend.